Global Growth Hormone Deficiency Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Growth Hormone Deficiency Market, By Type (Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency), Route of Administration (Intravenous, Intramuscular, Others), Treatment (Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, Surgery), Diagnosis (Blood Tests, Imaging Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

 

Growth Hormone Deficiency Market

Market Analysis and Size

In recent years, the growth hormone deficiency market is anticipated to grow rapidly during the forecast period. Growth hormone deficiency (GDH) affects less than one in 3,000 to one in 10,000 children in the United States, according to data provided by the American Academy of Pediatrics. GHD is a medical disorder marked by insufficient production of somatropin, a growth hormone, by the anterior pituitary gland, which is responsible for cell development and reproduction. Growth hormone insufficiency causes children to grow slowly and puberty to be delayed. Adults and children have different symptoms when it comes to growth hormone insufficiency. Growth hormone deficiency is treated with daily or weekly growth hormone injections, with the results of therapy being apparent after 2-3 months.

Data Bridge Market Research analyses that the growth hormone deficiency market was valued at USD 3,980.38 million in 2021 and is expected to reach USD 5,747.75 million by 2029, registering a CAGR of 4.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Growth hormone deficiency (GHD), often called dwarfism or pituitary dwarfism, is a disorder caused by a lack of growth hormone in the body. Children with GHD have a normal body proportions but are abnormally short in stature. GHD can be congenital (existing at birth) or develop over time (acquired). If the pituitary gland produces insufficient growth hormone, this disease develops. Genetic problems, a serious brain injury, or being born without a pituitary gland can all cause it.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Diseases (Hypertension, Dyslipidemia, Diabetes, Others), Treatment (Antiplatelet Agents, Beta-Blockers, Angiotensin-Converting Enzyme Inhibitors, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Zydus Cadila (India), AstraZeneca (UK), Johnson & Johnson (US), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Cipla Inc. (US), Ipsen Pharma (France), Novo Nordisk A/S (Denmark), Abbott (US), Allergan (Ireland)

Market Opportunities

 

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Growth Hormone Deficiency Market Dynamics

Drivers

  • Increasing incidences of growth disorders

The rising incidences of growth disorders is estimated to enhance the market's growth. Over time, there has been a gradual increase in public understanding concerning the use of synthetic growth hormone therapy. However, as industry participants have conducted more studies into the underlying causes of growth disorders and the rate of diagnosis has increased, the number of cases of growth disorders has increased. Pediatric growth hormone deficit, adult growth hormone deficiency, idiopathic low stature, and hereditary illnesses including Turner syndrome and Prader-Willi syndrome are just a few of these ailments.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of growth hormone deficiency market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get growth diseases, further estimated to enhance the market’s growth rate.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the growth hormone deficiency market. Additionally, changing lifestyles of people and rising prevalence of other genetic disorders will result in the expansion of growth hormone deficiency market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the growth hormone deficiency market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the growth hormone deficiency market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the growth hormone deficiency market. Additionally, strict regulatory policies and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This growth hormone deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the growth hormone deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Growth hormone deficiency affects about 1 in every 7,000 births. Prader-Willi syndrome is one of the hereditary illnesses that causes this condition.

Growth hormone deficiency market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Growth Hormone Deficiency Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The growth hormone deficiency market was hampered by the supply chain slowness.

Recent Development

  • In April 2021, the U.S. Food and Drug Administration (FDA) announced the approval of first once-weekly injection for pediatric growth hormone deficiency. Lonapegsomatropin-tcgd injection (Skytrofa, Ascendis) is approved for children weighing at least 11.5 kg who are experiencing growth failure due to insufficient endogenous growth hormone secretion.

Global Growth Hormone Deficiency Market Scope

The growth hormone deficiency market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Pediatric Growth Hormone Deficiency
  • Adult Growth Hormone Deficiency

Diagnosis

Treatment

  • Pharmacological Therapy
  • Recombinant Human Growth Hormone
  • Human Pituitary Gland Extracts
  • Surgery

Route of Administration

  • Intravenous
  • Intramuscular
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Growth Hormone Deficiency Market Regional Analysis/Insights

The growth hormone deficiency market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the growth hormone deficiency market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the growth hormone deficiency market because of the rising number of research activities in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to increasing cases of growth hormone deficiency in this region. Also, the development of healthcare infrastructure and the rising geriatric population will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Growth Hormone Deficiency Market Share Analysis

The growth hormone deficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to growth hormone deficiency market.

Some of the major players operating in the growth hormone deficiency market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Zydus Cadila (India)
  • AstraZeneca (UK)
  • Johnson & Johnson (US)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Bristol-Myers Squibb Company (US)
  • Eli Lilly and Company (US)
  • Cipla Inc. (US)
  • Ipsen Pharma (France)
  • Novo Nordisk A/S (Denmark)
  • Abbott (US)
  • Allergan (Ireland)

Research Methodology: Global Growth Hormone Deficiency Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The market value for Growth Hormone Deficiency Market is expected USD 5,747.75 million by 2029.
The Growth Hormone Deficiency Market is to grow at a CAGR of 4.70 % during the forecast by 2029.
The major players operating in the Growth Hormone Deficiency Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Zydus Cadila (India), AstraZeneca (UK), Johnson & Johnson (US), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Cipla Inc. (US), Ipsen Pharma (France), Novo Nordisk A/S (Denmark), Abbott (US), Allergan (Ireland).
The major countries covered in the Growth Hormone Deficiency Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.